Wide Ranks

CANF

Can-Fite Biopharma Ltd Sponsore

2.10

Top Statistics
Market Cap 13 M Forward PE -1.20 Revenue Growth -19.40 %
Current Ratio 2.93 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -450.35 Enterprise / Revenue 5256.31 Price To Sales Trailing12 Months 19.55
Profitability
Profit Margins 0.00 % Operating Margins -1295.57 %
Balance Sheet
Total Cash 4 M Total Cash Per Share 0.0030 Total Debt 57000
Total Debt To Equity 2.30 Current Ratio 2.93 Book Value Per Share 0.0010
All Measures
Short Ratio 166.00 % Message Board Id finmb_676937 Fax 972 3 924 9378
Shares Short Prior Month 215478 Return On Equity -1.58 City Ramat Gan
Uuid e519a042-0611-33ca-a018-d9c27252c89f Previous Close 2.05 First Trade Date Epoch Utc 1 B
Book Value 0.0010 Beta 0.5670 Total Debt 57000
Volume 84877 Price To Book 2100.00 Last Split Date 1 B
Fifty Two Week Low 1.87 Total Cash Per Share 0.0030 Total Revenue 667000
Shares Short Previous Month Date 1 B Target Median Price 12.00 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -1295.57 % Target Mean Price 13.33
Net Income To Common -7371000 Ask 2.12 Short Percent Of Float 0.0255
Implied Shares Outstanding 4 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 78690 Average Volume10days 78690 Total Cash 4 M
Next Fiscal Year End 1 B Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.05 Target Low Price 10.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.21 Open 2.10
Free Cashflow -4552625 Dividend Yield 0.00 % Return On Assets -0.5746
Time Zone Short Name EST Trailing Eps -2.60 Day Low 2.07
Address1 26 Ben Gurion Street Shares Outstanding 6 M Price Hint 4
Target High Price 18.00 Website https://www.canfite.com 52 Week Change -0.1064
Average Volume 101915 Forward Eps -0.7300 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 237.90 % Last Split Factor 1:10
Regular Market Day High 2.25 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 2.30 Fifty Two Week High 4.69 Day High 2.25
Shares Short 138665 Regular Market Open 2.10 Industry Key biotechnology
Bid 2.15 Earnings Growth 0.00 % Enterprise To Revenue 5256.31
Revenue Growth -19.40 % Shares Percent Shares Out 0.0227 Operating Cashflow -7431000
Currency USD Time Zone Full Name America/New_York Market Cap 13 M
Is_nasdaq_100 False Zip 5257346 Quote Type EQUITY
Industry Biotechnology Long Name Can-Fite BioPharma Ltd. Regular Market Day Low 2.07
Held Percent Institutions 0.1050 Current Price 2.10 Enterprise To Ebitda -450.35
Financial Currency USD Current Ratio 2.93 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country Israel
Float Shares 1 B Two Hundred Day Average 2.41 Enterprise Value 3 B
Price To Sales Trailing12 Months 19.55 Forward PE -1.20 Regular Market Volume 84877
Ebitda -7785000 Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Can-Fite BioPharma Ltd.

, a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.

The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.

It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.

In addition, the company develops commercial predictive biomarker blood test kit for A3AR.

It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.

The company was formerly known as Can-Fite Technologies Ltd.

and changed its name to Can-Fite BioPharma Ltd.

in January 2001.

The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.